ライフサイエンスコーパス: vaso-occlusive

1 ight attenuate the severity of outcomes from vaso-occlusive and hemolytic crises.

2 Unheralded vaso-occlusive cardiovascular events (myocardial infarct

3 ous cellular and soluble participants in the vaso-occlusive cascade.

4 emoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cel

5 Current treatments to reduce vaso-occlusive complications include chronic hydroxyurea

6 mbosis, but also impact on many of the other vaso-occlusive complications of SCD.

7 To determine whether early vaso-occlusive complications predicted subsequent advers

8 nt and pentoxifyllin therapy in another, the vaso-occlusive complications were eliminated.

9 pproval for shortening the duration of acute vaso-occlusive complications, likely highlighting the co

10 Non-DMT users had the lowest prevalence of vaso-occlusive crises (mean [SD], 0.8 [2.4]), acute ches

11 nconsistent users had a higher prevalence of vaso-occlusive crises (mean [SD], 3.7 [4.7]), splenic co

12 atients at steady state and 6 during painful vaso-occlusive crises (pVOC).

13 ry hemoglobinopathy characterized by painful vaso-occlusive crises (VOC) and chronic hemolysis.

14 Treatment of vaso-occlusive crises (VOC) or events in sickle cell dis

15 A unique feature of SCD is vaso-occlusive crises (VOCs) characterized by episodic,

16 al ischemia during acute sickle cell-related vaso-occlusive crises (VOCs) has been suggested.

17 c disorder causing painful and unpredictable Vaso-occlusive crises (VOCs) through blood vessel blocka

18 ia/reperfusion (H/R) stress, mimicking acute vaso-occlusive crises (VOCs), increased bone turnover, o

19 Six serious AEs (SAEs) included 4 vaso-occlusive crises (VOCs), non-VOC-related shoulder p

20 focus on health care utilization for painful vaso-occlusive crises (VOCs).

21 es of emergency department visits related to vaso-occlusive crises [VOC] and hospitalizations related

22 vels in subjects with severe SCD (at least 3 vaso-occlusive crises [VOCs] per year) were 18.5 +/- 1.2

23 ase, including the frequency and severity of vaso-occlusive crises and acute chest syndrome episodes.

24 Vaso-occlusive crises are the main acute complication in

25 tly targeted a reduction in the frequency of vaso-occlusive crises as an endpoint, but increasingly,

26 Vaso-occlusive crises at index admission were associated

27 ch as cold exposure are known to precipitate vaso-occlusive crises by still unclear mechanisms.

28 om from inpatient hospitalization for severe vaso-occlusive crises for at least 12 consecutive months

29 nce interval [CI], 83 to 100) were free from vaso-occlusive crises for at least 12 consecutive months

30 to 100) were free from hospitalizations for vaso-occlusive crises for at least 12 consecutive months

31 he primary end point was freedom from severe vaso-occlusive crises for at least 12 consecutive months

32 Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cel

33 ocirculation and is characterized by painful vaso-occlusive crises in deep tissues.

34 cell disease who had had at least two severe vaso-occlusive crises in each of the 2 years before scre

35 ism for the increased occurrence of clinical vaso-occlusive crises in individuals with sickle cell di

36 The SUSTAIN study showed a reduction of vaso-occlusive crises in patients treated with 5 mg/kg c

37 nhibitor ticagrelor vs placebo in preventing vaso-occlusive crises in pediatric patients with sickle

38 d or stress, which have been associated with vaso-occlusive crises in SCD.

39 e blood vessel wall, thereby contributing to vaso-occlusive crises in sickle cell disease.

40 hydroxyurea use to decrease the frequency of vaso-occlusive crises is completely defined only in 2 te

41 primary endpoint was the annualised rate of vaso-occlusive crises leading to a health-care visit ove

42 Ratios of adjusted annualised rates of vaso-occlusive crises leading to health-care visits were

43 alysis showed an adjusted annualised rate of vaso-occlusive crises of 2.49 (95% CI 1.90-3.26) in the

44 crises, number of ACS events, and number of vaso-occlusive crises requiring hospitalization or emerg

45 42, linking hemolysis- and infection-induced vaso-occlusive crises to TLR4 signaling.

46 t was not met: estimated yearly incidence of vaso-occlusive crises was 2.74 in the ticagrelor group a

47 In conclusion, no reduction of vaso-occlusive crises was seen with ticagrelor vs placeb

48 The primary end point was the rate of vaso-occlusive crises, a composite of painful crises and

49 e complications of SCD such as acute anemia, vaso-occlusive crises, and acute chest syndrome; and/or

50 line to week 72, the annualised incidence of vaso-occlusive crises, and patient functioning, as asses

51 ciated with milder disease phenotypes, fewer Vaso-occlusive crises, and reduced organ damage.

52 outcomes included the incidences of malaria, vaso-occlusive crises, and serious adverse events.

53 term reductions in the occurrence of painful vaso-occlusive crises, but the long-term safety and effi

54 od disorder that is characterized by painful vaso-occlusive crises, for which there are few treatment

55 mability and blood rheology in precipitating vaso-occlusive crises.

56 ckle cell anemia is characterized by painful vaso-occlusive crises.

57 ased total hemoglobin and HbF, and no severe vaso-occlusive crises.

58 evere chronic hemolytic anemia and iterative vaso-occlusive crises.

59 cterized by basal inflammation and recurrent vaso-occlusive crises.

60 cute presentations of osteomyelitis (OM) and vaso-occlusive crisis (VOC) bone infarction in children

61 Painful vaso-occlusive crisis (VOC) is the most common complicat

62 Vaso-occlusive crisis (VOC) is the primary cause of morb

63 a phase 3, randomized, controlled trial for vaso-occlusive crisis (VOC) requiring hospitalization (R

64 Severe ACS often develops in the course of a vaso-occlusive crisis (VOC), but currently there are no

65 HTRs induced acute vaso-occlusive crisis (VOC), resulting in shortened surv

66 SCD were evaluated at baseline (n = 36), in vaso-occlusive crisis (VOC; n = 12), and during ACS (n =

67 et of hydroxyurea (HU) treatment or during a vaso-occlusive crisis and at steady-state.

68 ry and secondary endpoints-rates of clinical vaso-occlusive crisis and hemolytic events, blood transf

69 ther, in men, and likely all patients during vaso-occlusive crisis and the acute chest syndrome, nitr

70 y (AKI), a risk factor for CKD, often during vaso-occlusive crisis associated with acute intravascula

71 gated the protective effect of IVIG on acute vaso-occlusive crisis caused by neutrophil recruitment a

72 t enrolment, and who had between one and ten vaso-occlusive crisis events in the previous 12 months w

73 The rate of vaso-occlusive crisis events per person-year was 2.30 in

74 mportance in the development of the hallmark vaso-occlusive crisis in sickle cell disease (SCD).

75 or dysregulation to the development of acute vaso-occlusive crisis in sickle cell disease have been i

76 The pathophysiology of vaso-occlusive crisis in sickle cell disease involves in

77 r the treatment or prevention of pain due to vaso-occlusive crisis in sickle cell disease nor reassur

78 nt disease-modifying therapy for alleviating vaso-occlusive crisis in sickle cell disease.

79 lium and inflammation play a central role in vaso-occlusive crisis in sickle cell disease.

80 , or who had been admitted to hospital for a vaso-occlusive crisis in the previous 14 days were exclu

81 Pain due to vaso-occlusive crisis is the major cause of hospital use

82 with varied patterns of health-care use and vaso-occlusive crisis management as well as the commerci

83 LA2 (steady state mean = 10.0 +/- 8.4 ng/mL; vaso-occlusive crisis mean = 23.7 +/- 40.5 ng/mL; ACS me

84 n patients with ACS but not in patients with vaso-occlusive crisis or non-SCD patients with pneumonia

85 ng the incidence of ACS adjusted for that of vaso-occlusive crisis over time.

86 Features of vaso-occlusive crisis pathophysiology such as red cell a

87 escents with sickle cell anemia, the rate of vaso-occlusive crisis was not significantly lower among

88 The primary end point was the rate of vaso-occlusive crisis, a composite of painful crisis or

89 ing 20 admissions for ACS, 10 admissions for vaso-occlusive crisis, and during 12 clinic visits when

90 or; monthly incidence of hospitalization for vaso-occlusive crisis, asthma crisis, and acute pyelonep

91 and may be a measurable laboratory marker of vaso-occlusive crisis.

92 symptomatic sickle cell disease nor in acute vaso-occlusive crisis.

93 of hospitalization in children with SCD and vaso-occlusive crisis.

94 tudy period, the most common being grade 2-3 vaso-occlusive crisis.

95 ickle cell disease (SCD) is characterized by vaso-occlusive crisis.

96 well as a link with acute chest syndrome and vaso-occlusive crisis.

97 suggest that INO may be beneficial for acute vaso-occlusive crisis.

98 whether heterozygosity of Nf1 would lead to vaso-occlusive disease in genetically engineered mice in

99 spholipid syndrome is a rare cause of ocular vaso-occlusive disease, but is associated with significa

100 lopathy, which mirrors features of human NF1 vaso-occlusive disease, identifies a potential therapeut

101 tress in the sickle mouse precipitates acute vaso-occlusive disease.

102 ically less than 3 days to attenuate rebound vaso-occlusive disease.

103 hereby participating in the pathogenesis of vaso-occlusive diseases.

104 thy, retinopathy of prematurity, and retinal vaso-occlusive diseases.

105 ivated VSMCs is a potential strategy against vaso-occlusive disorders such as in-stent restenosis, ve

106 CD98hc is a potential therapeutic target in vaso-occlusive disorders.

107 arbon emulsion (PFE) was tested for its anti-vaso-occlusive effects in the ex vivo mesocecum vasculat

108 Vaso-occlusive episode (VOE) is a common and critical co

109 rotective effect of ADAMTS13 but exacerbated vaso-occlusive episode in mice with SCA.

110 (VWF)-cleaving protease ADAMTS13 alleviated vaso-occlusive episode in mice with SCA.

111 th fixed-dose hydroxyurea indicate decreased vaso-occlusive episodes (0.60; 95% CI 0.52-0.70; p<0.000

112 CD patients experience erythrocyte sickling, vaso-occlusive episodes (VOE), and progressive organ dam

113 Vaso-occlusive episodes (VOEs) are a major concern in pa

114 Here, using vaso-occlusive episodes (VOEs) of sickle cell disease as

115 SCD patients suffer from acute vaso-occlusive episodes (VOEs), chronic organ damage, an

116 Vaso-occlusive episodes are the primary cause of emergen

117 r 188 reported shortened duration of painful vaso-occlusive episodes in SCD, particularly in children

118 proaches to both prevention and treatment of vaso-occlusive episodes in SCD.

119 tive agents are available to prevent painful vaso-occlusive episodes of sickle cell disease (SCD), th

120 e moderate to severe pain typical of painful vaso-occlusive episodes requiring hospitalization were i

121 d to be the initiating event in the periodic vaso-occlusive episodes that characterize sickle cell di

122 th a broad range of complications, including vaso-occlusive episodes, acute chest syndrome (ACS), pai

123 Hydroxyurea (HU) therapy results in fewer vaso-occlusive episodes, and we postulated that HU-relat

124 l apoptosis, and inflammation occur owing to vaso-occlusive episodes, hypoxia, and ischemic injury.

125 al of hydroxyurea to reduce the frequency of vaso-occlusive episodes, sickle cell disease (SCD) has c

126 This is a key factor in the initiation of vaso-occlusive episodes, the hallmark of SCD.

127 population of neutrophils that can stimulate vaso-occlusive episodes.

128 me to last dose of parenteral opioids during vaso-occlusive episodes.

129 do not support the use of poloxamer 188 for vaso-occlusive episodes.

130 and (in the patient with SCD) elimination of vaso-occlusive episodes.

131 d hypoxia could lead to an increased risk of vaso-occlusive episodes.

132 ease-modifying therapies for ongoing painful vaso-occlusive episodes; treatment remains supportive.

133 Clinical manifestations resemble a vaso-occlusive event and include edema, intraretinal hem

134 with SCD during acute pain associated with a vaso-occlusive event increases the calcium responses to

135 tations of tumor cells migrating away from a vaso-occlusive event.

136 c/anoxic focus, often triggered by a central vaso-occlusive event.

137 reatment reduced the median rate of clinical vaso-occlusive events (0 compared with 1.0 per year, P <

138 her key safety outcomes, sickle cell related vaso-occlusive events (16.7 [n=11] vs 21.9% [n=14]; diff

139 16D) expression and >80% reduction in severe vaso-occlusive events (secondary endpoints).

140 ed in this analysis was the number of severe vaso-occlusive events after LentiGlobin infusion among p

141 We hypothesized that sickling-induced vaso-occlusive events and attendant oxidative stress wil

142 e been shown in preclinical models to reduce vaso-occlusive events and improve cardiovascular functio

143 with studies showing a reduced incidence of vaso-occlusive events and reduced mortality.

144 nd Akti XII has immediate benefits for acute vaso-occlusive events and survival in SCD mice exceeding

145 of sustained haemolytic anaemia and episodic vaso-occlusive events drive the development of end-organ

146 on of venous thrombosis in vivo and inhibits vaso-occlusive events in a human sickle cell disease equ

147 M, we show that hematopoietic DREAM promotes vaso-occlusive events in microvessels following TNF-a ch

148 M, we show that hematopoietic DREAM promotes vaso-occlusive events in microvessels following TNF-alph

149 c cell-cell adhesion and aggregation mediate vaso-occlusive events in patients with sickle cell disea

150 r whether it has immediate benefits in acute vaso-occlusive events in SCD patients.

151 roved clinical efficacy for preventing acute vaso-occlusive events in severely affected adults.

152 erion that required a minimum of four severe vaso-occlusive events in the 24 months before enrollment

153 n infusion among patients with at least four vaso-occlusive events in the 24 months before enrollment

154 duce endothelial injury and facilitate acute vaso-occlusive events in transgenic SAD mice.

155 termine the contribution of LW activation to vaso-occlusive events in vivo, we investigated whether i

156 Vaso-occlusive events promote ischemia/reperfusion patho

157 This interaction may contribute to vaso-occlusive events that are an important cause of mor

158 concentration, reduce hemolysis, and prevent vaso-occlusive events that cause additional increases in

159 on and thus contribute to the association of vaso-occlusive events with physiologic stress.

160 d be evaluated, all had resolution of severe vaso-occlusive events, as compared with a median of 3.5

161 Hydroxyurea use reduced the incidence of vaso-occlusive events, infections, malaria, transfusions

162 cell free hemoglobin that in turn initiates vaso-occlusive events, we conclude that cleavage of PTP1

163 l disease (SCD) is characterized by repeated vaso-occlusive events, which result in substantial morbi

164 ocytes to endothelium and may play a role in vaso-occlusive events.

165 hemolysis and complete resolution of severe vaso-occlusive events.

166 tin-independent mechanism promotes remaining vaso-occlusive events.

167 s characterized by the painful recurrence of vaso-occlusive events.

168 There were no vaso-occlusive events.

169 anylate cyclase, causes similar increases in vaso-occlusive events.

170 olysis, improving blood flow, and preventing vaso-occlusive events.

171 e possible role played by such aggregates in vaso-occlusive events.

172 in inflammation, blood flow impairment, and vaso-occlusive events.

173 ue disease dominated by hemolytic anemia and vaso-occlusive events.

174 served in SCD and increases the incidence of vaso-occlusive events.

175 l was related to HbF levels and frequency of vaso-occlusive events.

176 for children and adolescents with recurrent vaso-occlusive events; recent evidence documents sustain

177 ences blood rheology and plays a key role in vaso-occlusive manifestations of sickle cell disease.

178 mon serious adverse event in both groups was vaso-occlusive pain (11 events in five [8%] patients wit

179 sed with hydroxyurea use, including rates of vaso-occlusive pain (98.3 vs. 44.6 events per 100 patien

180 mia (SCA) admitted to the hospital for acute vaso-occlusive pain (VOC).

181 95% confidence interval [CI], 0.34 to 0.54), vaso-occlusive pain crises (incidence rate ratio, 0.43;

182 dentified to support the occurrence of acute vaso-occlusive pain crises in individuals with SCT.

183 ial Doppler velocity >200 cm/s (n = 2), >/=3 vaso-occlusive pain crises per year (n = 12), or >/=2 ac

184 zed by chronic hemolytic anemia and episodic vaso-occlusive pain crises.

185 ncompassing 185 children hospitalized with a vaso-occlusive pain crisis and a reference group of 65 c

186 patients with sickle cell disease (SCD) with vaso-occlusive pain crisis.

187 3; 95% confidence interval [CI], 0.06-0.91), vaso-occlusive pain episodes (11 studies, 1219 participa

188 Vaso-occlusive pain episodes (VOE) cause severe pain in

189 onicities are often used during treatment of vaso-occlusive pain episodes (VOE), the major cause of m

190 comes acutely deficient in SCD patients with vaso-occlusive pain episodes (VOE).

191 The MSH analysis suggests that rates of vaso-occlusive pain episodes in these patients were unre

192 ted to initiate or contribute to sickle cell vaso-occlusive pain episodes.

193 nd is associated with increased incidence of vaso-occlusive pain events, acute chest syndrome episode

194 Acute, vaso-occlusive pain is the most characteristic complicat

195 malaria infection, non-malarial infections, vaso-occlusive pain, and acute chest syndrome.

196 nd keywords related to "sickle cell trait," "vaso-occlusive pain," and "death," yielding 18 of 1474 c

197 A composite SCA-related clinical outcome (vaso-occlusive painful crisis, dactylitis, acute chest s

198 SCD), which often occurs in the setting of a vaso-occlusive painful crisis.

199 globin, is characterized by inflammatory and vaso-occlusive pathologies.

200 ransduction in SS RBCs may contribute to the vaso-occlusive pathology observed in sickle cell disease

201 combination of antiangiogenic treatment and vaso-occlusive PDT.

202 erize, thereby reducing the frequency of the vaso-occlusive phenomena associated with the disease.

203 ypothesis that the ability of HU to ease the vaso-occlusive phenomena may, in part, be attributed to

204 integral part of the pathophysiology of the vaso-occlusive phenomenon in sickle cell anemia.

205 The results suggest that PMNs contribute to vaso-occlusive processes and endothelial cell injury in

206 r aggregate formation drive the inflammatory vaso-occlusive processes associated with sickle cell ane

207 rea (HU) acute administration in diminishing vaso-occlusive processes in sickle cell disease (SCD) mi

208 potentially visually devastating necrotizing vaso-occlusive retinitis affecting both healthy and immu

209 S) are important in governing whether or not vaso-occlusive sickle cell crises will occur.

210 re no data to support the diagnosis of acute vaso-occlusive sickle cell crisis as a cause of death in

211 function of the formation and persistence of vaso-occlusive thrombi that limit tumor blood supply.